• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·000952.SZ
Share

Hubei Guangji Pharmaceutical Co., Ltd. Stocks

CN¥ 5.94Last Updated 15.07.2026

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 288.62M

CN¥ 5.94
Key Takeaways

Risk factor

Meaningful price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Hubei Guangji Pharmaceutical Co., Ltd. engages in the production and operation of pharmaceutical raw materials, pharmaceutical preparations, and feed additives. It specializes in production of vitamin B2, B6 and pharmaceutical products. Vitamin B2, is also known as riboflavin. it is used in medicine APIs (Active Pharmaceutical Ingredient), feed additives, and food additives. Its products are divided into raw material series products and preparation series products. The series of raw materials are pharmaceutical grade, food grade, 98% feed grade, 80% feed grade nuclear yellow and riboflavin sodium phosphate. The preparation series products are oral solid preparations and large infusions. The company was founded on May 28, 1993 and is headquartered in Wuxue, China.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is overvalued on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 16:00

"There Aren't Enough IT Budgets to Go Around": What Does IBM's Historic Plunge Mean for the Stock Market?

15.07.2026 15:46

Morning in New York: New inflation data will set the tone for trading

15.07.2026 14:33

Where to Invest $1,000 Right Now: 4 Stocks to Consider in the Third Quarter

15.07.2026 13:49

Apple has found a startup that reduces the size of AI models. This could help it improve Siri

15.07.2026 11:45

HSBC has named Kaspi shares its top pick for July. Why does it expect them to rise by a third?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026